# Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel

> **NCT04523324** · PHASE4 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 577 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flublok™ Quadrivalent by Sanofi, Inc.
- **BIOLOGICAL:** VaxigripTetra™ by Sanofi, Inc.

## Key facts

- **NCT ID:** NCT04523324
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-31
- **Primary completion:** 2020-01-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 577 (ACTUAL)
- **Last updated:** 2023-11-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523324, "Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04523324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*